Mabwell's Strategic Entry into Malaysia with Denosumab Biosimilars Licensing Agreement

Mabwell Partners with Malaysian Firm for Denosumab Biosimilars

Mabwell, a prominent biopharmaceutical company known for its innovative approach, has made a significant move in the Southeast Asian market. On April 16, 2026, the company announced that it has secured a licensing and commercialization agreement with a strategic business partner in Malaysia. This agreement centers around Mabwell’s biosimilar products, MAILISHU and MAIWEIJIAN, which are akin to Prolia® and Xgeva®, respectively. Under the terms of this partnership, the Malaysian partner will take charge of the registration and commercialization processes, while Mabwell will oversee the development, production, and supply of these products.

The Malaysian market, with a population of nearly 36 million, offers a promising landscape, thanks to its robust pharmaceutical framework. The country's GDP is one of the highest in the Southeast Asian region, and its pharmaceutical industry, valued at approximately USD 3.4 billion in 2025, is expected to grow at a compound annual growth rate of 6%. This growth illustrates substantial market potential, making it an attractive environment for Mabwell’s biosimilars.

Huiguo Hu, a board member and senior vice president of Mabwell, expressed excitement about the collaboration, stating, "We are delighted to see that we have reached a collaboration on denosumab in another ASEAN country. Malaysia has an internationally aligned regulatory environment, strong regional recognition, and significant space for development."

The decision to enter the Malaysian market aligns with Mabwell's vision of providing quality healthcare solutions to more patients across the region, ensuring that effective treatments are accessible and affordable. With established regulatory compliance measures and expected strong commercial execution from its local partner, Mabwell is eager to expedite the registration and launch of these vital biosimilar products.

Mabwell's mission, centered on exploring life and benefiting health, further emphasizes its commitment to innovative treatments that address pressing global medical needs, particularly in oncology and aging-related conditions. The licensing agreement is not only a strategic advancement for Mabwell but also a pivotal step in broadening access to healthcare solutions in Malaysia, reinforcing the company’s position as a leader in biopharmaceutical innovation.

As Mabwell continues to expand its reach within the ASEAN market, this collaboration signifies a crucial development in increasing treatment options for patients while reinforcing Malaysia’s status as a key player in the pharmaceutical realm. The partnership holds promise for future growth and positive impact on public health outcomes in the region. Mabwell’s focus on quality and innovation positions it well to make a significant contribution to healthcare improvements throughout Southeast Asia.